Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Re: Insider ownership

When tallying insider ownership, you need to take into account not only regular shares, but also restricted shares and share-equivalent derivatives. A subset* of such holdings is shown in Form DEF 14A (annual proxy statement), which ENTA will be issuing for FY2024 in the next couple of weeks.

For FY2023, the DEF 14A issued on 1/26/24 showed that including derivatives CEO Jay Luly owned 1.5M shares (6.9% of the company), and that ENTA’s executive officers and directors as a group owned 3.1M shares (13.7% of the company)—see page 6:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001177648/000095017024007956/enta-20240126.htm

The above numbers from FY2023 should still be reasonably close.

*For an explanation of the derivatives that are included in Form DEF 14A, see the paragraph immediately preceding the table of holdings on page 6 in the above link.